Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received a notice from the State Drug Administration. The third indication of the company's injectable Ruikang trastuzumab was approved for listing, making it the first anti-HER2 product approved for colorectal cancer in China. Approved indications: For adult patients with HER2-positive colorectal cancer who have failed treatment with oxaliplatin, fluorouracil, and irinotecan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.